跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

1472000

USP

Norgestrel

United States Pharmacopeia (USP) Reference Standard

别名:

(±)-Norgestrel, (17α)-(±)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H28O2
CAS号:
分子量:
312.45
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

norgestrel

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

O[C@@]1([C@@]2([C@H]([C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC2)CC1)CC)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

WWYNJERNGUHSAO-XUDSTZEESA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Norgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Ethinyl Estradiol Tablets
  • Levonorgestrel
  • Norgestrel
  • Norgestrel and Ethinyl Estradiol Tablets
  • Norgestrel Tablets

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Health hazardExclamation mark

警示用语:

Danger

危险声明

危险分类

Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ondrej Mestak et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 28(10), 764-766 (2012-03-10)
We report the case of a female who had suffered from progressive lymphatic malformation in the orbito-temporal region since childhood. Many surgical interventions were performed, including radical excision and shunt drainage. Despite aggressive surgical treatment, recurrence was observed after every
Kai I Cheang et al.
Fertility and sterility, 96(2), 353-359 (2011-06-17)
To evaluate the effects of a commonly used combined hormonal oral contraceptive (OC) on carbohydrate metabolism in obese as compared with lean women. 6-month prospective study. Clinical research center at an academic medical center. Premenopausal nondiabetic women with body mass
Nozomi Donoyama et al.
Acupuncture in medicine : journal of the British Medical Acupuncture Society, 29(4), 304-306 (2011-10-22)
A 26-year-old top female athlete (height 157 cm), who took part in competitive sport similar to middle- and long-distance running, became amenorrhoeic in February 2009. In late May 2009, athletic amenorrhoea was diagnosed and a norgestrel-ethinyl estradiol combination (norgestrel 0.5
Sigrid Nyberg
Contraception, 87(6), 773-781 (2012-11-06)
The purpose of this study was to investigate how women without and with different severity of premenstrual symptoms react to treatment with a combined oral contraceptive containing 250-mcg norgestimate/35-mcg ethinyl estradiol (EE). Focus was placed on mood and physical symptoms.
Shan Liu et al.
Environmental science & technology, 47(18), 10266-10276 (2013-08-21)
Natural and synthetic progestagens in the environment have become a concern due to their adverse effects on aquatic organisms. Laboratory studies were performed to investigate aerobic biodegradation of norgestrel by bacteria from activated sludge in comparison with progesterone, and to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门